MDACC Study No:2004-0568 ( NCT No: NCT00507962)
Title:A Phase I Study Dose Escalation Clinical Study Of Hepatic Intraarterial Cisplatin, In Combination With Systemic Intravenous Liposomal Doxorubicin Administered Every Four Weeks to Patients With Advanced Cancer And Dominant Liver Involvement
Principal Investigator:Apostolia M. Tsimberidou
Treatment Agent:Cisplatin; Liposomal Doxorubicin
Study Status:Terminated
Study Description:The goal of this clinical research study is find the highest safe dose of
cisplatin that can be given with liposomal doxorubicin in the treatment of
advanced cancer involving the liver.
Hide details for General InformationGeneral Information

Disease Group:Breast; Cervix; Colon; Colorectal; Endometrial; Esophageal; Gallbladder; Gastric; Gastrointestinal; Genitourinary; Gynecology; Head And Neck; Kidney; Liver; Lung; Lymphoma; Melanoma; Pancreas; Prostate; Rectum; Sarcoma; Small Bowel; Testis; Unknown Primary; Uterus
Phase of Study:Phase I
Treatment Agents:Cisplatin
Liposomal Doxorubicin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Patients will be admitted for approximately 5-7 days until recovery from all
immediate treatment related toxicities
Supported By:N/A
Return Visit:Patients will return to MDACC for a clinical evaluation on a monthly basis
Home Care:The initial or loading doses of liposomal doxorubicin will be given in the
clinic. Subsequent doses may be given at home.

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Apostolia M. Tsimberidou
Dept:Investigational Cancer Therapeutics
For Clinical Trial Enrollment:713-792-4259
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults